Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled.

MedStar author(s):
Citation: Current Molecular Pharmacology. 2013 Jan 08PMID: 23302002Institution: Washington Cancer InstituteDepartment: Associate Dean for Research Development | MedStar HealthForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXED | Year: 2013ISSN:
  • 1874-4672
Name of journal: Current molecular pharmacologyAbstract: The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to anti-angiogenic therapy.All authors: Veytsman I, Aragon-Ching JB, Swain SMFiscal year: FY2013Date added to catalog: 2024-04-24
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 23302002 Available 23302002

The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to anti-angiogenic therapy.

English

Powered by Koha